Land V J, Thomas P R, Boyett J M, Glicksman A S, Culbert S, Castleberry R P, Berry D H, Vats T, Humphrey G B
Cancer. 1985 Jul 1;56(1):81-7. doi: 10.1002/1097-0142(19850701)56:1<81::aid-cncr2820560114>3.0.co;2-2.
Eighty-seven children with central nervous system (CNS) leukemia were randomized to receive either induction intrathecal chemotherapy (ITC) and cranial irradiation (CRT) plus maintenance ITC, or induction ITC and craniospinal irradiation (CSpRT) with no maintenance ITC. ITC consisted of six weekly injections of methotrexate, hydrocortisone, and arabinosylcytosine. Also, intensification of systemic induction and maintenance chemotherapy was given. CRT + ITC was given as CRT, 2400 rad in 12 fractions followed by ITC maintenance bimonthly for 2 years. Craniospinal irradiation consisted of CRT + 1400 rad in ten fractions to the spine. Randomization was stratified according to whether CNS leukemia occurred at initial diagnosis of acute lymphocytic leukemia (ALL) (Stratum I, 15 patients), during first bone marrow (BM) remission (Stratum II, 49 patients), simultaneous with first BM relapse (Stratum III, 12 patients), or during second BM remission (Stratum IV, 11 patients). The median follow-up for patients who remain at risk is 15 + months. Eight children (seven on CRT + ITC, one on CSpRT) developed presumed therapy related encephalopathy. In Stratum II, 16 of 29 (55%) patients receiving CRT + ITC experienced adverse events: 3 deaths during continuous complete remission (CCR) and 13 relapses (2 CNS, 1 CNS + BM, 1 BM + testes, and 2 testes) as compared with only 5 relapses in 20 (25%) patients on CSpRT (1 CNS, 1 CNS + BM, 1 BM, and 2 testes). The children on both regimens were comparable for sex, race, age at initial ALL diagnosis, time from ALL diagnosis to first episode of CNS leukemia, systemic therapy both before and after CNS relapse, and number of blasts in the spinal fluid at diagnosis of CNS leukemia. The conclusion is that children with isolated CNS leukemia can achieve prolonged survival with aggressive therapy, and that CSpRT is possibly less toxic and more likely than is CRT + ITC to prevent subsequent BM and testicular relapse (P less than 0.02), but not subsequent CNS relapse (P = 0.7). A possible systemic therapy effect of spinal irradiation is postulated to explain the superiority of CSpRT.
87例中枢神经系统(CNS)白血病患儿被随机分为两组,一组接受鞘内诱导化疗(ITC)及颅脑照射(CRT)加维持性ITC,另一组接受诱导性ITC及全脑脊髓照射(CSpRT)且无维持性ITC。ITC包括每周注射一次甲氨蝶呤、氢化可的松和阿糖胞苷,共6周。同时,还进行了强化的全身诱导和维持化疗。CRT + ITC方案为:先进行CRT,分12次给予2400拉德,随后每两个月进行一次ITC维持治疗,共2年。全脑脊髓照射包括CRT加对脊髓分10次给予1400拉德。随机分组根据CNS白血病是在急性淋巴细胞白血病(ALL)初诊时发生(I层,15例患者)、首次骨髓(BM)缓解期发生(II层,49例患者)、与首次BM复发同时发生(III层,12例患者)还是在第二次BM缓解期发生(IV层,11例患者)进行分层。仍处于风险中的患者的中位随访时间为15 +个月。8名儿童(7名接受CRT + ITC,1名接受CSpRT)发生了疑似与治疗相关的脑病。在II层,接受CRT + ITC的29例患者中有16例(55%)出现不良事件:3例在持续完全缓解(CCR)期间死亡,13例复发(2例CNS复发、1例CNS + BM复发、1例BM + 睾丸复发和2例睾丸复发),而接受CSpRT的20例患者中只有5例复发(1例CNS复发、1例CNS + BM复发、1例BM复发和2例睾丸复发)。两种治疗方案的患儿在性别、种族、ALL初诊时的年龄、从ALL诊断到CNS白血病首次发作的时间、CNS复发前后的全身治疗以及CNS白血病诊断时脑脊液中的原始细胞数量方面具有可比性。结论是,孤立性CNS白血病患儿通过积极治疗可实现长期生存,且CSpRT可能毒性较小,比CRT + ITC更有可能预防随后的BM和睾丸复发(P < 0.02),但不能预防随后的CNS复发(P = 0.7)。推测脊髓照射可能具有全身治疗作用来解释CSpRT的优势。